Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms

Biomarker Research

Woodrow J Coker¹  Ashley Jeter¹  Henning Schade¹  Yubin Kang¹ 

[1] Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Hollings Cancer Center, Room# HO307, Charleston, SC, 29425, USA

关键词: Hematopoietic stem cell transplantation;    Outcome;    Treatment;    Molecular mechanism;    Epidemiology;    Multiple myeloma;    Gammopathy;    AIDS;    HIV;   

Others  :  792100
DOI  :  10.1186/2050-7771-1-8

 received in 2012-11-07, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Highly active antiretroviral therapy (HAART) has significantly improved the outcome and survival of human immunodeficiency virus (HIV)-infected patients. Subsequently, long-term morbidities including cancer have become of major public health and clinical interest for this patient population. Plasma cell disorders occur at higher incidence in HIV-infected patients; however, the molecular mechanisms driving the plasma cell disease process and the optimal management for these patients remain to be defined. This article provides an up-to-date review of the characteristics and management of HIV-infected patients with plasma cell disorders. We first present 3 cases of plasma cell disorders in HIV-infected patients, ranging from polyclonal hypergammaglobulinemia to symptomatic multiple myeloma. We then discuss the epidemiology, clinical presentation, and management of each of these plasma cell disorders, with an emphasis on the molecular events underlying the progression of plasma cell diseases from monoclonal gammopathy to symptomatic multiple myeloma. We propose a three-step hypothesis for the development of multiple myeloma. Finally, we discuss the use of high dose chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of HIV-infected patients with multiple myeloma. Our review includes the care of HIV-infected patients with plasma cell disorders in the current era of HAART and novel agents available for the treatment of multiple myeloma.

【 授权许可】

   
2013 Coker et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, Cazein F, Vittecoq D, Desenclos JC: Differential improvement in survival among patients with AIDS after the introduction of HAART. AIDS Care 2007, 19(4):523-531.
• [2]Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005, 10(6):412-426.
• [3]Dezube BJ, Aboulafia DM, Pantanowitz L: Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read 2004, 14(7):372-374. 377–379
• [4]Becker N: Epidemiology of multiple myeloma. Recent Results Cancer Res 2011, 183:25-35.
• [5]Konstantinopoulos PA, Pantanowitz L, Dezube BJ: Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites–the unknown role of underlying HIV infection. J Natl Med Assoc 2006, 98(11):1860-1861.
• [6]Fiorino AS, Atac B: Paraproteinemia, plasmacytoma, myeloma and HIV infection. Leukemia 1997, 11(12):2150-2156.
• [7]Rajkumar SV, Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005, 80(10):1371-1382.
• [8]Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24(6):1121-1127.
• [9]Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM: Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992, 89(2):561-566.
• [10]De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, Grutzmeier S, Sonnerborg A, Chiodi F: Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004, 103(6):2180-2186.
• [11]Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA: Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol 2007, 128(4):596-603.
• [12]Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354(13):1362-1369.
• [13]Lefrere JJ, Debbia M, Lambin P: Prospective follow-up of monoclonal gammopathies in HIV-infected individuals. Br J Haematol 1993, 84(1):151-155.
• [14]Briault S, Courtois-Capella M, Duarte F, Aucouturier P, Preud’Homme JL: Isotypy of serum monoclonal immunoglobulins in human immunodeficiency virus-infected adults. Clin Exp Immunol 1988, 74(2):182-184.
• [15]Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 2006, 43(9):1198-1205.
• [16]Smith A, Howell D, Patmore R, Jack A, Roman E: Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011, 105(11):1684-1692.
• [17]Frisch M, Biggar RJ, Engels EA, Goedert JJ: Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001, 285(13):1736-1745.
• [18]Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002, 16(8):1155-1161.
• [19]Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20(12):1645-1654.
• [20]Dal Maso L, Franceschi S, Polesel J, Braga C, Piselli P, Crocetti E, Falcini F, Guzzinati S, Zanetti R, Vercelli M, et al.: Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer 2003, 89(1):94-100.
• [21]Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, et al.: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97(6):425-432.
• [22]Newnham A, Harris J, Evans HS, Evans BG, Moller H: The risk of cancer in HIV-infected people in southeast England: a cohort study. Br J Cancer 2005, 92(1):194-200.
• [23]Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
• [24]Dal Maso L, Franceschi S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003, 4(2):110-119.
• [25]Muller S, Kohler H: B cell superantigens in HIV-1 infection. Int Rev Immunol 1997, 14(4):339-349.
• [26]Seligmann M, Brouet JC: Antibody activity of human myeloma globulins. Semin Hematol 1973, 10(2):163-177.
• [27]Potter M: Myeloma proteins (M-components) with antibody-like activity. N Engl J Med 1971, 284(15):831-838.
• [28]Pelicci PG, Knowles DM, Arlin ZA, Wieczorek R, Luciw P, Dina D, Basilico C, Dalla-Favera R: Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med 1986, 164(6):2049-2060.
• [29]Chong Y, Ikematsu H, Ariyama I, Chijiwa K, Li W, Yamaji K, Kashiwagi S, Hayashi J: Evidence of B cell clonal expansion in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2001, 17(16):1507-1515.
• [30]Konrad RJ, Kricka LJ, Goodman DB, Goldman J, Silberstein LE: Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N Engl J Med 1993, 328(25):1817-1819.
• [31]Lefrere JJ, Fine JM, Lambin P, Muller JY, Courouce AM, Salmon C: Monoclonal gammopathies in asymptomatic HIV-seropositive patients. Clin Chem 1987, 33(9):1697-1698.
• [32]Papadopoulos NM, Costello R, Ceroni M, Moutsopoulos HM: Identification of HIV-specific oligoclonal immunoglobulins in serum of carriers of HIV antibody. Clin Chem 1988, 34(5):973-975.
• [33]Ng VL, Chen KH, Hwang KM, Khayam-Bashi H, McGrath MS: The clinical significance of human immunodeficiency virus type 1-associated paraproteins. Blood 1989, 74(7):2471-2475.
• [34]Voelkerding KV, Sandhaus LM, Kim HC, Wilson J, Chittenden T, Levine AJ, Raska K Jr: Plasma cell malignancy in the acquired immune deficiency syndrome. Association with Epstein-Barr virus. Am J Clin Pathol 1989, 92(2):222-228.
• [35]Kumar S, Kumar D, Schnadig VJ, Selvanayagam P, Slaughter DP: Plasma cell myeloma in patients who are HIV-positive. Am J Clin Pathol 1994, 102(5):633-639.
• [36]Cannon MJ, Flanders WD, Pellett PE: Occurrence of primary cancers in association with multiple myeloma and Kaposi’s sarcoma in the United States, 1973–1995. Int J Cancer 2000, 85(4):453-456.
• [37]Le Gars L, Agbalika F, Picard O, Kaplan G, Berenbaum F: HHV8 status in Kaposi’s sarcoma associated with multiple myeloma. Rev Rhum Engl Ed 1998, 65(12):788-790.
• [38]Santon Roldan A, De San JS, Gomez Sanz E, Fernandez Munoz R, Herrera P, Bellas Menendez C: [Human herpesvirus-8 detection in Kaposi’s sarcoma, multiple myeloma, and lymphoproliferative syndromes occurring in immunocompetent and immunocompromised patients]. Med Clin (Barc) 2002, 119(7):241-244.
• [39]Marcelin AG, Dupin N, Bouscary D, Bossi P, Cacoub P, Ravaud P, Calvez V: HHV-8 and multiple myeloma in France. Lancet 1997, 350(9085):1144.
• [40]MacKenzie J, Sheldon J, Morgan G, Cook G, Schulz TF, Jarrett RF: HHV-8 and multiple myeloma in the UK. Lancet 1997, 350(9085):1144-1145.
• [41]Cottoni F, Uccini S: Kaposi’s sarcoma-associated herpesvirus infection and multiple myeloma. Science 1997, 278(5345):1972. author reply 1972–1973
• [42]Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, Treon SP, Fingeroth JD, et al.: Detection of Kaposi’s sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood 1999, 93(5):1482-1486.
• [43]Macchia D, Parronchi P, Piccinni MP, Simonelli C, Mazzetti M, Ravina A, Milo D, Maggi E, Romagnani S: In vitro infection with HIV enables human CD4+ T cell clones to induce noncognate contact-dependent polyclonal B cell activation. J Immunol 1991, 146(10):3413-3418.
• [44]Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2(3):175-187.
• [45]Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, Ludwig T, Rajewsky K, Dalla-Favera R: Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006, 7(7):773-782.
• [46]Rui L, Schmitz R, Ceribelli M, Staudt LM: Malignant pirates of the immune system. Nat Immunol 2011, 12(10):933-940.
• [47]Bergsagel PL, Kuehl WM: Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003, 194:96-104.
• [48]Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106(1):296-303.
• [49]Dang CV: MYC on the path to cancer. Cell 2012, 149(1):22-35.
• [50]Soucek L, Evan GI: The ups and downs of Myc biology. Curr Opin Genet Dev 2010, 20(1):91-95.
• [51]Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R: Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011, 25(6):1026-1035.
• [52]Zingone A, Kuehl WM: Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011, 48(1):4-12.
• [53]Kuehl WM, Bergsagel PL: MYC addiction: a potential therapeutic target in MM. Blood 2012, 120(12):2351-2352.
• [54]Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, et al.: AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13(2):167-180.
• [55]Holien T, Vatsveen TK, Hella H, Waage A, Sundan A: Addiction to c-MYC in multiple myeloma. Blood 2012, 120(12):2450-2453.
• [56]Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8(1):33-40.
• [57]Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001, 115(2):279-286.
• [58]Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM: Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010, 115(17):3541-3552.
• [59]Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S: Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem 2011, 286(39):34036-34050.
• [60]Tagoug I, Sauty De Chalon A, Dumontet C: Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One 2011, 6(7):e22641.
• [61]Abdi J, Engels F, Garssen J, Redegeld F: The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 2011, 80(2):225-240.
• [62]Chiron D, Jego G, Pellat-Deuceunynck C: Toll-like receptors: expression and involvement in multiple myeloma. Leuk Res 2010, 34(12):1545-1550.
• [63]Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang Y, Chang W, Zhu Z, Feng Y, Wu D: Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 2010, 150(5):543-553.
• [64]Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, et al.: Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107(1):301-304.
• [65]Zou W, Amcheslavsky A, Bar-Shavit Z: CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem 2003, 278(19):16732-16740.
• [66]Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
• [67]Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al.: Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471(7339):467-472.
• [68]Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, et al.: Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120(5):1067-1076.
• [69]Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, et al.: Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120(5):1060-1066.
• [70]Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, et al.: Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012, 120(5):1077-1086.
• [71]Bahlis NJ: Darwinian evolution and tiding clones in multiple myeloma. Blood 2012, 120(5):927-928.
• [72]Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P, Mathas S, Dorken B, Bargou RC: In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002, 100(9):3311-3318.
• [73]Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, et al.: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21(5):1079-1088.
• [74]Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J: Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004, 64(6):2016-2023.
• [75]Katzel JA, Hari P, Vesole DH: Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007, 57(5):301-318.
• [76]Neri P, Bahlis NJ: Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 2012, 12(7):776-796.
• [77]Tricot G: New insights into role of microenvironment in multiple myeloma. Lancet 2000, 355(9200):248-250.
• [78]Edwards CM, Zhuang J, Mundy GR: The pathogenesis of the bone disease of multiple myeloma. Bone 2008, 42(6):1007-1013.
• [79]Epstein J, Yaccoby S: Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 2003, 4(5):310-314.
• [80]Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, et al.: Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012, 119(24):5782-5794.
• [81]Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al.: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113(18):4341-4351.
• [82]Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR: Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95(3):1056-1065.
• [83]Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, et al.: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68(1):190-197.
• [84]Huff CA, Matsui W: Multiple myeloma cancer stem cells. J Clin Oncol 2008, 26(17):2895-2900.
• [85]Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, et al.: Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007, 104(10):4048-4053.
• [86]Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346(8):564-569.
• [87]Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005, 106(3):812-817.
• [88]Rajkumar SV, Kyle RA, Buadi FK: Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010, 85(10):945-948.
• [89]Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al.: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78(1):21-33.
• [90]Blade J, Kyle RA: Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998, 30(5–6):493-501.
• [91]Feller L, White J, Wood NH, Bouckaert M, Lemmer J, Raubenheimer EJ: Extramedullary myeloma in an HIV-seropositive subject. Literature review and report of an unusual case. Head Face Med 2009, 5:4. BioMed Central Full Text
• [92]Pouli A, Lemessiou H, Rontogianni D, Papanastassiou C, Tsakanikas S, Gerassimou A, Stamatelou M: Multiple myeloma as the first manifestation of acquired immunodeficiency syndrome: a case report and review of the literature. Ann Hematol 2001, 80(9):557-560.
• [93]Stewart JM, Krishnamurthy S: Fine-needle aspiration cytology of a case of HIV-associated anaplastic myeloma. Diagn Cytopathol 2002, 27(4):218-222.
• [94]Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group: Br J Haematol. 2003, 121(5):749-757.
• [95]Cauda R, Lucia MB, Marasca G, Rutella S, Petrucci MT, La Verde G, Gastaldi R: Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy. Eur J Haematol 1999, 63(2):134-135.
• [96]Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y, Markowitz M, Ho DD, et al.: HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998, 188(2):233-245.
• [97]Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG: Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005, 41(9):1326-1332.
• [98]Gimeno LS E, Abella E, Perez-Vila E, Cervera M, Montero M, Gimenez MT, Knobel H, Besses C: Complete remission of smoldering myeloma in an hiv patient after highly antiretroviral therapy. Haematologica 2007, 92(suppl2):485. Abstract 1348 2007
• [99]Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H: HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 2004, 3(4):473-479.
• [100]Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W, Hollander MC, Dennis PA: Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012, 3:e353.
• [101]Kyle RA, Rajkumar SV: Multiple myeloma. Blood 2008, 111(6):2962-2972.
• [102]Aboulafia DM: Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. AIDS Read 2003, 13(8):383-389.
• [103]Elira Dokekias A, Moutschen M, Purhuence MF, Malanda F, Moyikoua A: [Multiple myeloma and HIV infection: report of 3 cases]. Rev Med Liege 2004, 59(2):95-97.
• [104]Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK: Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol 2012, 89(5):432-434.
• [105]Kentos A, Vekemans M, Van Vooren JP, Lambermont M, Liesnard C, Feremans W, Farber CM: High-dose chemotherapy and autologous CD34-positive blood stem cell transplantation for multiple myeloma in an HIV carrier. Bone Marrow Transplant 2002, 29(3):273-275.
• [106]Gorschluter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, Schmidt-Wolf IG, Mey U: CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: a retrospective study. Leuk Lymphoma 2007, 48(3):506-512.